April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Study may explain why prostate tumor cells become resistant to hormone therapy
February 3rd 2005Certain mutations in the androgen receptor protein appear to cause advanced and invasive prostate cancer, at least in a mouse model, according to a recent study in the Proceedings of the National Academy of Sciences (2005; 102:1151-6).
Look for vulvodynia in patients with IC, pelvic pain
February 1st 2005Oak Brook, IL--Patients with interstitial cystitis may also have vulvodynia, another pelvic pain syndrome that isn't well understood and can be difficult to treat. But research is beginning to tease out the sources of pain, and therapies aimed at treating neuropathic pain seem to offer the most effective approach to treatment today.
Interferon is safe, effective for Peyronie's disease
February 1st 2005Buenos Aires, Argentina--For men with Peyronie's disease with or without erectile dysfunction, intralesional interferon alfa-2b (Intron-A) may offer a simple, safe, and effective treatment for improving penile curvature and the ability to have sexual intercourse. So say Cleveland Clinic researchers, who presented the results of a study on the drug in this population at the International Society for Sexual and Impotence Research world congress here.
Oral drug effectively improves premature ejaculation
February 1st 2005Buenos Aires, Argentina--The serotonin transport inhibitor dapoxetine appears to be a well-tolerated and effective agent for the treatment of premature ejaculation, according to the results of a phase II study presented at the International Society for Sexual and Impotence Research world congress.
Alternative therapies weighed for PCa prevention
February 1st 2005Chicago--In the wake of the surprising results of the Prostate Cancer Prevention Trial (PCPT), researchers continue to investigate possible therapies for prostate cancer prevention. Some focus on alternative therapies, with a major effort underway to determine the possible efficacy of selenium and vitamin E in the form of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Rethinking the PCPT: New panel convening
February 1st 2005Chicago--A panel of experts is expected to convene to reconsider the controversial findings of the Prostate Cancer Prevention Trial (PCPT), in particular, the indication that finasteride (Proscar) may prevent prostate cancer and yet lead to more severe grades of cancer in those men who develop it.
Transient patency is a problem after vasovasostomy
January 1st 2005Philadelphia--Even after vasovasostomy success, there is a chance that transient patency the "shutting down" of viable sperm production may occur, say researchers from the University of Alabama, Medical College of Wisconsin, and University of Iowa.
Guidelines advise on thrombotic events in urology
January 1st 2005Toronto--Although few published studies exist on the prevention of thromboembolic disorders in urologic surgery, the risk of such disorders appears to be similar to that seen in other major surgical procedures.Therefore, urologists should concentrate on identifying patients at sufficient risk to warrant routine thromboprophylaxis, said the co-author of a new set of antithrombotic guidelines from the American College of Chest Physicians.
Long-term data show agent to be effective, well tolerated in OAB patients
December 23rd 2004Extended-release tolterodine tartrate (Detrol LA) significantly reduces symptoms of overactive bladder with a low occurrence of side effects, according to results of a study published in Drug Safety (2004; 27:1043-57).
Satraplatin or active metabolite kills prostate cancer in vitro
December 9th 2004Treatment of prostate cancer cells with satraplatin or its active metabolite resulted in the killing of tumor cells, according to a poster presented at the American Association for Cancer Research's Basic, Translational, and Clinical Advances in Prostate Cancer meeting.
Medicare revenue for urologists will drop 14% in 2005
December 1st 2004Washington--The Centers for Medicare & Medicaid Services has published its final rule implementing the 2005 Medicare fee schedule, and it's not good news for urologists-especially those who administer cancer drugs in their offices.
Relationship found between LUTS, ED in men with BPH
December 1st 2004San Diego--A moderately strong association has been found between lower urinary tract symptoms and the rate of erectile dysfunction in men with moderate to severe symptoms of BPH and enlarged prostate glands, according to a presentation of data gleaned from the Proscar Long-Term Efficacy and Safety Study (PLESS).
Seed migration unlikely to cause adverse events
December 1st 2004Extraprostatic seed placement during prostate brachytherapy frequently results in seed migration to the thorax. However, this occurrence apparently does not influence dosimetry or cause adverse effects, suggest results of a Mayo Clinic series.